Isovurex (Ezetimibe)

Ezetimibe blocks the NPC1L1 transporter on the surface of intestinal cells, preventing the absorption of dietary and biliary cholesterol. This reduction in intestinal cholesterol uptake lowers the amount of cholesterol delivered to the liver, which in turn increases LDL‑receptor activity and enhances removal of LDL cholesterol from the bloodstream.

The appropriate dose of Isovurex is determined by the prescribing healthcare professional based on the patient’s clinical condition, laboratory results, and response to therapy. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

Safety data for ezetimibe in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To order Isovurex, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to ezetimibe is statin therapy, which reduces cholesterol synthesis in the liver. Ezetimibe works by inhibiting intestinal absorption, and it can be used alone or in combination with statins for additive LDL‑cholesterol lowering. Unlike statins, ezetimibe does not affect hepatic cholesterol synthesis, which may be advantageous for patients who cannot tolerate high‑dose statins.

Isovurex should be stored at room temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight and heat sources. Do not store in the bathroom or near a kitchen sink where humidity is high.

Isovurex is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events, although rare, include myopathy (muscle pain or weakness), severe allergic reactions such as rash or breathing difficulty, and cholestatic hepatitis, which presents with jaundice and elevated liver enzymes. Patients should seek immediate medical attention if they experience any of these symptoms.

Isovurex is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminases. Individuals with known hypersensitivity to ezetimibe or any of the tablet’s excipients should also avoid the medication. Clinicians should evaluate liver function before initiating therapy.